Capsugel adds European micro-dosing capacity

By Gareth Macdonald contact

- Last updated on GMT

iStock/pisit38
iStock/pisit38

Related tags: Kohlberg kravis roberts, Henry kravis

Rumoured IPO-ready Capsugel has added micro-dose capabilities at its facility in Ploërmel, France citing its acquisition of Xcelience as the driver for the expansion.

The New Jersey, US capsule maker said it had replicated micro-dosing operations at Xcelience​'s facility in Tampa Florida at the French site in order to be closer to European customers.

Amit Patel, President, Capsugel Dosage Form Solutions said: "By leveraging best practices pioneered by Xcelience, an array of Xcelodose technologies and our high-containment capability, we have further strengthened our speed-to-product toolkit​.”

Xcelience provides specialized clinical trial manufacturing and supply services for a broad range of solid dosage forms, as well as development and manufacturing for specialized products such as highly potent and controlled substance compounds.

Capsugel bought Xcelience in December last year in a deal that expanded the dosage form solutions business it launched in February 2013​.

The Xcelience acquisition, like that of Powdersize that it bought at the same time, are part of the strategy Capsugel has followed since it entered the dosage form solutions space.

In March 2013 Capsugel acquired Encap​. The following October​ it bought Bend Research.

Capsugel said it plans to continue innovating and expanding its micro-dosing technology and service offering.

Takeover or IPO?

In April Reuters​ reported last week that Capsugel is "preparing to explore a sale or an initial public offering (IPO)​" suggesting that Danaher, 3M, Becton-Dickinson, Thermo Fisher Scientific, Bayer and Catalent.

Capsugel's owner US private equity investor Kohlberg Kravis Roberts (KKR) - which acquired the firm from Pfizer in 2011 – has not commented on the report.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers